In the past week, CLOV stock has gone down by -2.58%, with a monthly gain of 4.38% and a quarterly surge of 4.05%. The volatility ratio for the week is 4.66%, and the volatility levels for the last 30 days are 4.19% for Clover Health Investments Corp The simple moving average for the past 20 days is -3.04% for CLOV’s stock, with a 54.95% simple moving average for the past 200 days.
Is It Worth Investing in Clover Health Investments Corp (NASDAQ: CLOV) Right Now?
Company’s 36-month beta value is 1.96.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CLOV is 377.31M, and currently, short sellers hold a 4.05% ratio of that floaft. The average trading volume of CLOV on December 16, 2024 was 7.18M shares.
CLOV) stock’s latest price update
Clover Health Investments Corp (NASDAQ: CLOV)’s stock price has soared by 3.38 in relation to previous closing price of 3.11. Nevertheless, the company has seen a loss of -2.58% in its stock price over the last five trading days. seekingalpha.com reported 2024-12-11 that Clover Health Investments shows financial progress and challenges in 2024, with a focus on innovative Medicare Advantage plans and technology-driven healthcare solutions. The company achieved a 4.0 rating for its PPO plan, indicating improved quality of care and potential for higher CMS reimbursements. Despite a slight membership decline, Clover’s financial efficiency has improved, with net income losses decreasing significantly from 2022 to 2024.
Analysts’ Opinion of CLOV
Many brokerage firms have already submitted their reports for CLOV stocks, with UBS repeating the rating for CLOV by listing it as a “Neutral.” The predicted price for CLOV in the upcoming period, according to UBS is $4 based on the research report published on October 07, 2024 of the current year 2024.
Cowen, on the other hand, stated in their research note that they expect to see CLOV reach a price target of $3, previously predicting the price at $7. The rating they have provided for CLOV stocks is “Market Perform” according to the report published on February 02nd, 2022.
Canaccord Genuity gave a rating of “Buy” to CLOV, setting the target price at $6 in the report published on February 02nd of the previous year.
CLOV Trading at -11.80% from the 50-Day Moving Average
After a stumble in the market that brought CLOV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.74% of loss for the given period.
Volatility was left at 4.19%, however, over the last 30 days, the volatility rate increased by 4.66%, as shares surge +5.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.30% lower at present.
During the last 5 trading sessions, CLOV fell by -2.42%, which changed the moving average for the period of 200-days by +272.17% in comparison to the 20-day moving average, which settled at $3.32. In addition, Clover Health Investments Corp saw 237.67% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLOV starting from Garipalli Vivek, who purchase 531,700 shares at the price of $1.88 back on Aug 09 ’24. After this action, Garipalli Vivek now owns 1,409,267 shares of Clover Health Investments Corp, valued at $999,596 using the latest closing price.
Garipalli Vivek, the Director of Clover Health Investments Corp, purchase 877,567 shares at $1.14 during a trade that took place back on Jun 17 ’24, which means that Garipalli Vivek is holding 877,567 shares at $1,000,426 based on the most recent closing price.
Stock Fundamentals for CLOV
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.34 for the gross margin
The net margin for Clover Health Investments Corp stands at -0.06. The total capital return value is set at -0.24. Equity return is now at value -28.69, with -11.12 for asset returns.
Currently, EBITDA for the company is -210.84 million with net debt to EBITDA at 3.07. When we switch over and look at the enterprise to sales, we see a ratio of 0.86. The receivables turnover for the company is 21.02for trailing twelve months and the total asset turnover is 2.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.55.
Conclusion
In a nutshell, Clover Health Investments Corp (CLOV) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
